Company intelligence / Profile preview

Pulip

Bedford, Massachusetts, United Statesgetpulip.com ↗

Ownership: Private
Development stage: Commercial

Overview

Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases and central nervous system disorders using its proprietary iSPERSE™ dry powder delivery technology. Its lead programs include PUR3100 for acute migraine, which has completed Phase 1 with promising pharmacokinetic results and is preparing for Phase 2, as well as other candidates in rare lung diseases such as ABPA and cystic fibrosis-related fungal infections.

Therapeutic areas: PulmonologyNeurologyInfectious Diseases
Modalities: Small moleculeBiologicDry powder inhalation therapy (via iSPERSE technology)
Industry: Biotech

Partnerships

Capsugel/Lonza – manufacturing collaboration for spray-dried particle candidates and scale-up of iSPERSE-based products

Beyond the preview

Go deeper on Pulip.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulip.

Explore the full profile